Exact Sciences Q4 Results Beat Analysts Expectations
Madison-based Exact Sciences Corp. released fourth-quarter results on Tuesday that beat analysts' expectations. The company, best known for its colon cancer test Cologuard, posted a fourth-quarter loss of $127.7 million, or $0.72 per share, on revenue of $553 million. The Associated Press reported that the average estimate of eight analysts polled by Zacks Investment Research … Read more